Gao Jia, Lv Fang, Li Jia, Wu Zongyong, Qi Jun
Clinical Laboratory, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Department of Thoracic Surgery, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
PLoS One. 2014 Jul 9;9(7):e101979. doi: 10.1371/journal.pone.0101979. eCollection 2014.
CK19-2G2, a new fragment of cytokeratin 19, is a potential tumor marker for diagnosing lung cancer. The preoperative level of serum CK19-2G2 has been demonstrated to be associated with tumor metastasis and survival of breast cancer patients. This study investigated the postoperative dynamic changes in serum CK19-2G2 levels and its clinical significance in lung cancer patients.
Preoperative serum CK19-2G2 levels were measured in 630 lung cancer patients and were compared with individuals with benign pulmonary diseases (n = 134) and healthy volunteers (n = 263). In 352 cases, the patients underwent surgery. In these patients, in addition to preoperative assays, serum CK19-2G2 was also monitored at 1 week and 1 month after the operation.
The preoperative baseline levels of serum CK19-2G2 was significantly higher in lung cancer patients than patients with benign diseases and healthy controls (P<0.001). The postoperative levels of CK19-2G2 declined significantly within 1 week after tumor resection. Hereafter, a further decrease was observed in the patients who underwent palliative operations, while for the patients in the radical resection group, their CK19-2G2 levels stabilized.
CK19-2G2 may be a candidate marker for diagnosing and monitoring a patient's response to lung cancer treatment. In addition, CK19-2G2 may be an indicator for micrometastases in lung cancer patients.
细胞角蛋白19的新片段CK19-2G2是诊断肺癌的一种潜在肿瘤标志物。血清CK19-2G2的术前水平已被证明与乳腺癌患者的肿瘤转移和生存相关。本研究调查了肺癌患者术后血清CK19-2G2水平的动态变化及其临床意义。
检测了630例肺癌患者的术前血清CK19-2G2水平，并与患有良性肺部疾病的个体（n = 134）和健康志愿者（n = 263）进行比较。在352例患者中，这些患者接受了手术。在这些患者中，除了术前检测外，还在术后1周和1个月监测血清CK19-2G2。
肺癌患者术前血清CK19-2G2的基线水平显著高于良性疾病患者和健康对照（P<0.001）。肿瘤切除后1周内，CK19-2G2的术后水平显著下降。此后，接受姑息手术的患者进一步下降，而根治性切除组的患者，其CK19-2G2水平稳定。
CK19-2G2可能是诊断和监测患者对肺癌治疗反应的候选标志物。此外，CK19-2G2可能是肺癌患者微转移的一个指标。
